Protalix reports interim Phase II data for UC candidate

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) reported interim data from the first 14 patients with mild to moderate ulcerative colitis (UC) who completed an open-label, Israeli Phase II trial evaluating once-daily 2 and 8 mg OPRX-106 for eight weeks. At week eight, OPRX-106 led to a clinical response in 57% of patients and clinical remission in 36% of patients. Response and remission rates were secondary endpoints and were measured by the Mayo Clinic score. Additionally, 79% of patients showed an improvement on the Mayo Clinic rectal bleeding subscore.

On other secondary endpoints, 86% of patients showed improvement in fecal calprotectin levels and 64% achieved histopathological improvement as measured by the Geboes scale...